Agenus Inc. Selling, General and Administrative Expense of Revenue

Selling, General and Administrative Expense of Revenue of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative Expense of Revenue for the quarter ending June 29, 2020 was 52.68% (a -24.9% decrease compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative Expense of Revenue decreased by -8.75%
  • Annual Selling, General and Administrative Expense of Revenue for 2019 was 30.68% (a -69.78% decrease from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2018 was 101.51% (a 29.0% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2017 was 78.69% (a -46.38% decrease from previous year)
  • Twelve month Selling, General and Administrative Expense of Revenue ending June 29, 2020 was 50.4% (a -6.25% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative Expense of Revenue increased by 41.53% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
50.4% 53.76% 30.68% 35.61%
Visit stockrow.com/AGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative Expense of Revenue of Agenus Inc.

Most recent Selling, General and Administrative Expense of Revenueof AGEN including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative Expense of Revenue of Agenus Inc.

Agenus Inc. Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 52.68% 70.15%
2019 35.71% 57.73% 72.57% 13.52% 30.68%
2018 150.74% 71.89% 59.67% 545.72% 101.51%
2017 117.12% 239.65% 193.37% 28.82% 78.69%
2016 155.48% 182.34% 107.96% 154.92% 146.75%
2015 110.74% 93.57% 125.7% 138.8% 114.32%
2014 311.28% 314.68% 199.3% 716.26% 304.55%
2013 858.97% 486.11% 574.96% 260.68% 475.63%
2012 242.69% 297.76% 535.83% 21.49% 71.83%
2011 420.94% 392.67% 338.8% 428.47% 392.63%
2010 317.43% 420.26% 343.69% 380.83% 360.5%
2009 461.1% 392.2% 423.18%

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Further, it develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bifunctional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. Additionally, the company engages in the development INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390 – an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.